Since 1986 - Covering the Fastest Computers in the World and the People Who Run Them

Language Flags
April 20, 2010

The Possibilities of Cloud in the Life Sciences Industry

Bruce Maches

I am excited to have this opportunity to blog about the impact and usage of cloud-based HPC computing technologies on the life sciences industry. I have seen a lot of new technologies come and go in my 32 years in IT and feel that cloud computing will have a tremendous positive impact on life science companies. To offer a bit of background, my experience ranges from junior programmer to CIO/Director—I’ve spent more than half my career either working with or consulting to many life science companies such as Pfizer, Lilly, Amylin, Abbott Vascular, and Elan.

Since this is the first blog entry I thought I would provide some background information on the industry and commonly used terms, the drug development R&D process, FDA regulatory environment and current industry challenges.

The term life science is a rather loose definition but encompasses three basic types of companies:
 
• Pharmaceuticals – this usually refers to the big multi-product firms such as Pfizer, Lilly, Merck, Glaxo Smith Kline etc.

• Bio-tech – loosely defines smaller research oriented companies that are focused on one product or one therapeutic area, many not commercialized yet
 

• Medical device – companies that make products that can be used externally or internally in the body and range from tongue depressors to artificial hearts 

These types of companies make up the life science industry and all operate under the regulatory guidelines put forth by the Food & Drug Administration (FDA). The amount of regulatory scrutiny varies greatly depending on the product in question, obviously a company making bandages or an elbow brace would have a much lower regulatory hurdle to pass than a company making heart valve replacements. The IT organizations in these companies must adhere to the FDA guidelines put forth in the Code for Federal Regulations 21 Part 11 – or CFR 21 Part 11, which defines how systems managing electronic records in life science firms must be validated and verified to ensure that the operation of and the information in these systems can be trusted. I will provide more background on CFR 21 Part 11 compliance in another post.

The life science R&D process can be a long and expensive endeavor with current averages of getting a new drug from molecule to market being 10 years and over $900 million for new therapies. It is a terribly expensive process with many new products or drugs not panning out. Added to this dynamic is the fact for new drugs that the exclusive patent has only a life of 20 years before generic competition can emerge. Since the filing of the patent starts prior to the full development process the exclusivity period for the patent after a product comes to market usually ranges from 8 to 10 years. This means that every day you can take off of the development and approval process can translate into millions of dollars in extra sales for a large block buster drug.

The product development process varies by type of drug or device but follows these basic steps which I describe at a very high level:

• Phase 1 – identification of the molecule, initial testing, toxicology studies

• Phase 2 – further development, formulation, human testing

• Phase 3 – full scale double blind clinical trials to test efficacy, submission for FDA approval 

There are many areas where cloud computing can improve and speed up this process by reducing IT complexity and cost while allowing R&D organizations to focus on the ‘what’ of the R&D process in stead of the ‘how’.

Here are some of the topics related to cloud computing and the life sciences that I will be covering in future blog entries.

• Managing/reducing drug development expenses using cloud based technologies
 

• Dealing with the increasingly complex R&D process

• How cloud computing can help in reducing time to market for new therapies

• Facilitation FDA regulatory compliance

• How cloud computing can facilitate the increasing use of complex models (human genome) in the drug R&D process

• Supporting complex data analytics

• How to better manage the exploding amount of data generated as part of the R&D process

• Migration of legacy systems to the cloud

• Data access, regulatory and security issues

I look forward to exploring these topics in-depth and hearing your thoughts and your inputs. If there are other subjects you would like explored please feel free to let me know.

SC14 Virtual Booth Tours

AMD SC14 video AMD Virtual Booth Tour @ SC14
Click to Play Video
Cray SC14 video Cray Virtual Booth Tour @ SC14
Click to Play Video
Datasite SC14 video DataSite and RedLine @ SC14
Click to Play Video
HP SC14 video HP Virtual Booth Tour @ SC14
Click to Play Video
IBM DCS3860 and Elastic Storage @ SC14 video IBM DCS3860 and Elastic Storage @ SC14
Click to Play Video
IBM Flash Storage
@ SC14 video IBM Flash Storage @ SC14  
Click to Play Video
IBM Platform @ SC14 video IBM Platform @ SC14
Click to Play Video
IBM Power Big Data SC14 video IBM Power Big Data @ SC14
Click to Play Video
Intel SC14 video Intel Virtual Booth Tour @ SC14
Click to Play Video
Lenovo SC14 video Lenovo Virtual Booth Tour @ SC14
Click to Play Video
Mellanox SC14 video Mellanox Virtual Booth Tour @ SC14
Click to Play Video
Panasas SC14 video Panasas Virtual Booth Tour @ SC14
Click to Play Video
Quanta SC14 video Quanta Virtual Booth Tour @ SC14
Click to Play Video
Seagate SC14 video Seagate Virtual Booth Tour @ SC14
Click to Play Video
Supermicro SC14 video Supermicro Virtual Booth Tour @ SC14
Click to Play Video